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Abstract For more than a decade, researchers have been
trying to develop non-invasive imaging techniques for the in
vivo measurement of viable pancreatic beta cells. However, in
spite of intense research efforts, only one tracer for positron
emission tomography (PET) imaging is currently under clini-
cal evaluation. To many diabetologists it may remain unclear
why the imaging world struggles to develop an effective
method for non-invasive beta cell imaging (BCI), which could
be useful for both research and clinical purposes. Here, we
provide a concise overview of the obstacles and challenges
e n c o u n t e r e do nt h ew a yt os u c hB C I ,i nb o t hn a t i v ea n dt r a n s -
planted islets. We discuss the major difficulties posed by the
anatomical and cell biological features of pancreatic islets, as
well as the chemical and physical limits of the main imaging
modalities, with special focus on PET, SPECT and MRI. We
conclude by indicating new avenues for future research in the
field, based on several remarkable recent results.
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Abbreviations
BCI Beta cell imaging
BCM Beta cell mass
CEST Chemical exchange saturation transfer
CT Computed tomography
[
18F]-DOPA [
18F]Fluoro-L-dihydroxyphenylalanine
DTBZ Dihydrotetrabenazine
[
18F]-FDG [
18F]Fluorodeoxyglucose
GLP-1R Glucagon-like peptide 1 receptor
NMI Nuclear medicine imaging
PARACEST Paramagnetic chemical exchange saturation
transfer
PET Positron emission tomography
SPECT Singlephotonemissioncomputedtomography
SPIO Superparamagnetic iron oxide particle
VMAT2 Vesicular monoamine transporter 2
Introduction
Our current knowledge about the beta cell mass (BCM) in
normal individuals and diabetic patients largely relies on
autopsy data [1]. By necessity, these are single time-point
evaluations. It is important to develop a non-invasive means
ofmonitoring BCM asa function oftime, tobetterunderstand
the development and courseof type 1 and type 2 diabetes, and
to evaluate the effects of novel candidate glucose-lowering
drugs, which may modify the BCM [2]. Researchers have
been tackling this problem for about 15 years. Since then,
the National Institutes of Health (Bethesda, MD, USA) have
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DOI 10.1007/s00125-012-2491-7organised four workshops on beta cell imaging (BCI) [3]. The
first European workshop on BCI took place in Stockholm,
Sweden, on the occasion of the annual EASD meeting in
2010. Despite this drive, and some promising initial observa-
tions [4], progress has been hindered by many problems, so
that only one tracer (dihydrotetrabenazine [DTBZ]), which
targets vesicular monoamine transporter 2 (VMAT2), is cur-
rently under clinical evaluation for positron emission tomog-
raphy (PET) imaging of pancreatic islets [5]. Of concern,
quantitative measurement of the signal for this tracer remains
challenging [6], and questions about the suitability of the
target and the specificity of the tracer remain [7]. To many
diabetologists it may not be clear why the imaging world
strugglestodevelopasimpleandeffectivemethodforclinical,
non-invasive BCI, especially since developments towards the
molecular characterisation of tumours and techniques for im-
aging the consequences of metabolic disorders have become a
reality in other biomedical fields. Here, we review the
obstacles hindering the development of clinical BCI (Fig. 1).
A first challenge in the quest to adapt existing techni-
ques for BCI is that the target is a diffuse collection of cell
clusters, dispersed throughout the pancreas, that consti-
tutes less than 2% of the total mass of the adult gland.
This volume is likely to decrease during the course of
diabetes [2]. Therefore, BCI requires either a high spatial
resolution or a high ‘chemical resolution’, meaning, a
highly specific tracer molecule that targets beta cells but
not the surrounding exocrine pancreas. Present anatomical
clinical imaging modalities, such as computed tomogra-
phy (CT) or clinical MRI, cannot resolve individual islets
of Langerhans, which typically range from 20 to 600 μm
in diameter. On the other hand, functional clinical imaging
modalities with very high sensitivity, such as PET or
single photon emission computed tomography (SPECT)
are hampered by the partial volume effect, leading to an
underestimation of the signals derived from objects
smaller than the spatial resolution of the scanner. Another
problem is that imaging modalities have either a high
sensitivity (SPECT, PET) or a high spatial resolution
(CT, MRI), but rarely have a combination of both charac-
teristics in a clinically useful mode. Furthermore, the
sensitivity of tracer-based imaging is dependent on the
level of expression of the target. In radiotracer imaging
of tumours, the target is usually overexpressed on the
tumour cells in comparison to the healthy tissue, thus
leading to higher accumulation [8–10]. This is also the
case for the endocrine pancreas. In insulinomas, for ex-
ample, the density of the glucagon-like peptide 1 receptor
(GLP-1R) is considerably higher than in normal pancreas
(mean density of 8,302±1,073 dpm/mg in benign human
insulinomas vs. 1,563±104 dpm/mg in normal endocrine
pancreas) [10, 11]. This difference presumably explains
why tracers such as [
18F]fluoro-L-dihydroxyphenylalanine
([
18F]-DOPA) that are suitable for imaging insulinomas
and nesidioblastosis by targeting D2 receptors [12]a r e
not adequate for imaging the native beta cells.
Beta cell
Small cell size
Viability/functionality
Target expression
Diffuse localisation
Diffusion capacity
Metabolic trapping
Tracer retention
Specificity
Affinity TtB ratio
Background
PVE
Sensitivity
Resolution
Motion artefacts
Scan duration
Stability
Tracer size
Chemical resolution
Clearance (kidney)
Modality Tracer
Fig. 1 The three main groups
of obstacles encountered on the
way to clinical beta cell
imaging: modality, tracer and
beta cells themselves. PVE,
partial volume effect; TtB,
target-to-background ratio
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sufficient for therapy may not suffice for imaging) and size
of tracer molecules (large molecules are retained in blood
and have a lower diffusion capacity, resulting in low target-
to-background ratios). Several more hurdles, such as the site
of transplantation, confront the imaging of transplanted
islets. For metabolic and physiological reasons, the liver is
the preferred site for islet transplantation, but their diffuse
distribution throughout the sinusoid vascular bed vastly
complicates the detection of the grafted islets. When islets
are pre-labelled, as is generally the case for MRI [4], large
loads of label are required, which may alter islet viability
and function.
Thus, it is evident that in vivo BCI is challenging, and
that each imaging technology is associated with a number of
trade-offs, owing to the nature of the imaging equipment,
the tracer molecules used and the characteristics of the islets
of Langerhans (see text box). The situation recalls that faced
by the mythical Greek heroes Odysseus, Jason and Aeneas,
navigating between Scylla and Charybdis. Each of them
chose different solutions: Odysseus sacrificed some of his
sailors, Jason asked for the help of goddess Hera and
Comments Potential  or  actual  solutions
tal pancreatic volume and show low
levels of target expression   use a highly sensitive imaging modality, 
such as PET/SPECT 
proves image quality and accuracy of 
quantification   correction is possible in MRI 
ments hampers visualisation of the 
pancreatic islets. Correction for these movements is difficult   develop 
pharmacology to block the movements, as well as ultrafast imaging 
sequences 
vely localise individual islets (and
pancreas in small animals)   possible in high-field MRI 
s surroundings, may hinder imaging of  the 
transplanted islets   use a hydrophilic tracer cleared via the kidney when
islets are transplanted into the liver (in patients) or use lipophilic tracers 
(cleared by the liver) when islets are  transplanted under the kidney 
capsule (in animals) 
 neighbouring organs (liver, kidneys, bladder) 
must be considered   develop modified tracers
Expression of targets might vary in different pathological conditions, such
as inflammation and/or rejection   validate the candidate targets under 
conditions thought to prevail in diabetes 
al damage due to pre-labelling   test 
different contrast agents and minimise their concentration  
her cells/extracellular matrix at the site of islet
transplant or uptake by resident phagocytes might occur   develop beta 
cell-specific tracers 
d long-lasting   develop tracers with 
fast blood clearance and prolonged beta cell labelling 
Issues confounding BCI
Issue
Native islet imaging
Sensitivity Beta cells represent less than 2% of to
Breathing motion Correction for breathing motion im
Irregular motion Liver, stomach and intestinal move
Resolution High resolution is necessary to conclusi
Transplanted islet imaging – in vivo targeting
Site of islet transfer The implanted organ, and it
Non-specific background High non-specific uptake in
Physiological status of the
graft
Transplanted islet imaging – ex vivo labelling
Additional damage Islets might suffer from addition
Non-specific label transfer Non-specific loss to ot
Label retention Label retention should be stable an
Fate of label after cell death Clearance of label from damaged islets by phagocytes, which provide a 
false signal (only if the contrast agent and/or phagocytes remain at the site
of transplantation) 
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still uncertain which approach, or combination thereof,
will work for BCI. In the following sections, we discuss
these limitations and the challenges faced by the differ-
ent imaging modalities.
Radionuclide imaging (PET/SPECT)
Radionuclide imaging is based on the specific uptake of a
radiolabelled tracer, and the subsequent detection of γ pho-
tons emitted by the decaying nuclide. Nuclear medicine
imaging (NMI) techniques such as PETand SPECT provide
three-dimensional images of the distribution of the tracer.
Moreover, NMI accurately quantifies radioactivity concen-
trations in the picomolar range and provides information on
the kinetics of tracer distribution. In contrast, the per-
formance of PET and SPECT is comparatively poor in
terms of spatial resolution (>1 mm). Thus, it is still not
possible to visualise single pancreatic islets with NMI,
especially in clinical scanners, where PET performs better
(spatial resolution of 2–4 mm) than SPECT (spatial resolution
of 8–10 mm) and the determination of BCM requires high
accumulationofaradiotracerthatspecificallylabelsbetacells.
Native islets
For in situ detection of native islets, it has been estimated
that the uptake/binding of a tracer should be 1,000 times
higher in beta cells than in other cell types [13]. For exam-
ple, the dopamine D2-like receptor was considered an
attractive target [14], but attempts to determine the
BCM by [
18F]-DOPA PET failed because of the high
uptake of the tracer in the exocrine pancreas, limiting
the usefulness of this tracer to detect focal nesidioblas-
tosis [15, 16]. In the latter situation, high numbers of
insulin-producing cells form clusters that are larger than
most islets, and these occupy a substantial fraction of
the neonatal pancreas. As an alternative, targeting
VMAT2 with radiolabelled DTBZ has now been tested.
In humans, VMAT2 is present in beta cells [17, 18]a n d
in the sympathetic nerves throughout the gastrointestinal
tract and pancreas [19]. Thus, despite specific VMAT2
targeting in vitro, a high and non-specific uptake of
radiolabelled DTBZ has been observed in the exocrine
pancreas[7,19–21].Thisimportantnon-betacellbindingmay
explain the modest decrease in DTBZ uptake observed in
long-term type 1 diabetic patients and in rodent models of
the disease. Inthis case a 50% decrease inbinding isobserved
relative to healthy controls, in spite of the fact that at
least 90% of the beta cells are lost [6, 22–24]. There-
fore, it is unlikely that the tracer could detect the small
differences in BCM anticipated in type 2 diabetes.
Ideally, uptake by other endocrine cells of the islets
should also be minimal. The sulfonylurea SUR1 recep-
tor, which has been considered for determination of BCM
[25, 26], is expressed by all islet cell types, and thus may give
ambiguous results. Furthermore, several radiolabelled SUR1
ligands have low and non-specific uptake in the pancreas and
high uptake in adjacent organs [27, 28].
GLP-1R is mostly expressed on beta cells, with lower
levels of expression on alpha and gastric parietal cells [29].
Exendin, which is a natural ligand of GLP-1R, is extensively
taken up by islets and less by the exocrine pancreas. Unfortu-
nately, kidneyuptakeofexendin isalsohigh[30].Preliminary
data on the determination of the BCM in rat models of
diabetes using GLP-1R targeting are promising [31]. Also,
Reiner et al [32] showed that GLP-1R could be targeted by
exendin-4 conjugated with a near-infrared fluorophore for
intravital fluorescent imaging [32], which supports the idea
of GLP-1R imaging as a valid approach.
As mentioned above, radiotracers with high specific activ-
ity should result in a high beta cell-to-background ratio. How-
ever, even if a radiotracer is highly specific, this does not
automatically translate into target identification in scin-
tigraphic scans. For instance, when clearance from the
blood is low, non-specific signal from circulating tracer
may hamper the detection and quantification of the
specific signal from beta cells. Therefore, both a high
radioactive uptake ratio of endocrine-to-exocrine pancreas
and a high radioactive uptake ratio of pancreas-to-
surrounding organs and blood are necessary. For example,
the monoclonal islet cell surface antibody IC2 specifically
targetsbetacells,andtheuptakeof
125I-labelledIC2correlates
linearly with BCM in the mouse [33]. However, the slow
clearance of this monoclonal antibody from the blood, which
is due to the large immunoglobulin size, is likely to limit its
application in humans. F(ab′)2 fragments, single chain anti-
bodies, nanobodies and Affibodies may be interesting alter-
natives, since they have specificities and affinities towards the
target that are similar to those of native antibodies but have a
faster clearance as the result of a much smaller size. Unfortu-
nately, most of these immunoglobulin forms feature high
kidney uptake. Another alternative is the single-chain anti-
bodies produced by phage-display technology, which show
high uptake in the rat pancreas, a linear correlation with BCM
and fast blood clearance [34].
Excretion routes also significantly affect the target-to-
background ratios. Hydrophilic molecules are generally
cleared via the kidneys, whereas lipophilic and large mole-
culesarecleared via the hepatobiliarysystem. Renalclearance
can result in unspecific tubular absorption of radiolabelled
peptides, and the close proximity to the pancreas may hamper
BCI [35]. Co-injection of lysine, poly-glutamic acid or a
gelatine-based plasma expander together with the radiola-
belled tracer reduces, but does not completely block,
1250 Diabetologia (2012) 55:1247–1257unspecific renal uptake [35]. Clearance via the hepatobiliary
system results in high accumulation of tracers in the liver and
might also result in excretion via the intestinal organs, leading
to enhanced radioactivity concentrations in the intestinal tract.
In turn, high intestinal uptake will decrease the pancreas-to-
background ratio. This is the case for
11C- and
18F-labelled
DTBZ, which are under clinical evaluation [7, 19–21]. The
introduction of a hydrolysable epoxide shifts the route of
excretion from the liver to the kidney, resulting in lower
accumulation in non-target organs [36].
Another important aspect of an ideal tracer for BCI is the
specific activity, i.e. the amount of radioactivity (usually
expressed in becquerels, Bq) attached to a given amount of
tracer molecule (usually expressed in moles). The high
activity doses that are required for imaging the small sized
islets, may temporarily block the target and reduce its tracer
accumulation [37, 38]. In the case of exendin, the optimal
dose for targeting GLP-1R is 20 pmol [38]. This requires a
specific activity of more than 500 GBq/μmol to enable BCI
by SPECT, using
111In-DTPA-exendin [39]. This is in con-
trast to pharmacological approaches, where an excess of
certain drugs is often applied to achieve the maximum
therapeutic effect. Moreover, tracers that require higher
injected doses may cause side effects, especially when bio-
logically active compounds/derivatives (e.g. GLP-1 ana-
logues or SUR1 agonists) are used.
Tracer stability also plays a major role in successful
imaging, since chemically unstable molecules have low or
no accumulation in target cells. For instance,
125I-labelled
dithizone, a chelator of heavy metals, which stains beta cells
in vivo owing to their high zinc content [40], is rapidly
cleaved, releasing
125I in biological fluids [41]. Conjugation
of histamine increases the stability of the radio-iodinated
dithizone, but this modification results in high uptake in the
liver and exocrine pancreas [42, 43], making this approach
useless for BCI. Most peptides are prone to degradation by
endogenous peptidases, usually resulting in lower receptor
affinity and/or biological activity. For example, somatostatin
has a plasma half-life of less than 3 min in humans [44] and
the introduction of D-amino acids and a reduced C-terminus
increases the plasma half-life of the somatostatin analogue
octreotide [44–47]. These modifications have made octreo-
tide a suitable ligand for the somatostatin receptor, leading
to its widespread use in the imaging of neuroendocrine
tumours [48, 49]. However, structural modifications of pep-
tides often reduce their binding affinity and/or internalisa-
tion kinetics and, thus, tracer uptake. Prevention of peptide
degradation can also be achieved by conjugation to a large
protein, such as albumin. As an example, GLP-1 conjugated
to albumin prolongs GLP-1R signalling [50]. However, this
conjugation results in slower clearance as a result of the
larger size of the complex, leading to a lower pancreas-to-
background ratio.
Transplanted islets
Transplantation of pancreatic islets of Langerhans is a prom-
ising treatment for type 1 diabetic patients. The ability of islet
transplantation to normalise blood glucose levels is encourag-
ing [51], even though the rate of insulin-independency drops
tolessthan15% after 5 years.In viewofthe considerableside
effects caused by the immunosuppressive therapy required in
islet transplantation, a more favourable outcome should be
reached. A method that would allow us to specifically visual-
ise transplanted beta cells in vivo in humans could be a key
factor in improving the outcome of islet transplantation. If
such a method could monitor the islet graft function, which to
date can onlybeindirectlyestimatedbybloodglucose,insulin
and C-peptide levels, a relationship between BCM and beta
cell function could be determined.
Results of the first successful in vivo imaging of an islet
graft were published in 2004 [52]. Islets were transfected with
an adenoviral vector coding for the luciferase gene [52]. A
similar approach was used by the same group, using PET. In
this case, the islets were transfected with a reporter gene,
leading to trapping of the PET probe in islet grafts, which
could then be visualised in vivo [53]. In another study, PET
was also successfully used for imaging islets that expressed a
reporter gene under the control of the insulin promoter. The
signal obtained by PET directly correlated with insulin pro-
duction [54]. Although this groundbreaking work has shown
the feasibility ofinvivoimagingoftransplantedbeta cells,the
necessity toeithergeneticallymodifythe betacellsortoinfect
them with viruses currently limits the use of these technolo-
gies to animal experimentation. In another experiment, post-
transplantation events could be monitored for up to 6 h fol-
lowing ex vivo pre-labelling of islets with [
18F]fluorodeoxy-
glucose ([
18F]-FDG) [55]. However, the method does not
allow for long-term follow-up, given the short half-life of
18F (110 min) and the possibility of pre-labelling islets only
once.Intheoptimalsituationthe tracershouldtargetbetacells
in vivo, enabling multiple imaging sessions in the same indi-
vidual at multiple defined time-points.
Despite the overall progress of these approaches, imaging
of transplanted islets remains technically demanding in
humans. Indeed, the existing techniques require manipula-
tion of the islets prior to transplantation for pre-labelling,
genetic modification or viral infection. Therefore, there is an
urgent need to develop a tracer that would enable simple,
reproducible and safe in vivo imaging of transplanted beta
cells in patients.
MRI
MRI has several advantages over NMI, including relatively
easy clinical application, no involvement of radioactive
Diabetologia (2012) 55:1247–1257 1251isotopes and suitability for both repeated and long-term
imaging. MRI has high spatial resolution, permitting up to
single cell imaging under appropriate conditions [56, 57].
Furthermore, MRI is not limited by tissue penetration and
shows endogenous soft tissue contrast, thus providing ex-
quisite anatomical context. However, MRI is less sensitive
than NMI techniques and is therefore presently more adapt-
able to imaging pre-labelled islets rather than native islets in
situ. This is because pre-labelling typically achieves higher
label concentration in the relevant cells, with lower back-
ground because of the lack of non-specific uptake. MRI
sensitivity depends on several factors, including the imaging
hardware, the sample homogeneity, the amount of contrast
agent loaded in the cells, the imaging sequences used, the
density of cells and, in some cases, the intracellular local-
isation of the contrast agent. The useful concentration of a
contrast agent may therefore vary, although nanomolar
concentrations are usually required for superparamagnetic
iron oxide particles (SPIOs). MRI acquisition can be slow
when high resolution is required and is therefore susceptible
to motion artefacts. While the effects of breathing motion can
be prevented by synchronising the image acquisition with the
respiratory cycle, abdominal and peristaltic motion are more
difficult to correct [58].
Native islets
Direct imaging of unlabelled islets is not yet possible using
standard clinical systems owing to limited resolution (beyond
the average islet size) and the poor differential contrast of
isletscomparedwiththe surrounding pancreatic tissue. There-
fore, a first strategy is to use indirect means to evaluate BCM
andisletfunction.Forexample,bloodoxygenleveldependent
(BOLD) and arterial spin labelling (ASL) imaging do not
require the use of external contrast agents and can be quanti-
fied [59, 60]. So far, however, the early success in preclinical
models has not been reproduced in clinical studies [61].
Therefore, other approaches are now being developed to label
islets in situ, prior to MRI.
One such approach uses dynamic MRI techniques to mea-
sure blood flow and vessel permeability. Changes in vascula-
ture are expected to relate to changes in islet function and
revascularisation after transplantation. The use of MRI to
study vascularisation was originally developed to study
tumour vascularisation in vivo. Microvascular leakage
measurement using injectable SPIOs can detect pancre-
atic inflammation and its reversal after immunosuppres-
sive therapy [62]. A recent study in mice using dynamic
gadolinium-enhanced contrast imaging found that peak
signal enhancement (a measure of vascularisation) occurred
7 days after islet transplantation in the liver. In this case the
MRI data correlated with the neovascularisation of the grafts,
asassessedbyhistologicalanalysis[63].Increasedmanganese
levels result in a change in contrast [57, 64], which enables
visualisation of individual islets under experimental 14.1 T
fieldconditions[57].Whetherthemanganesecontrastinforms
about beta cell function, remains to be fully validated. How-
ever, the injection of contrast agents at larger doses than those
used for ex vivo cell labelling may be toxic, possibly com-
promising clinical use. Recently, a small scale human trial
exploited the changes in vascular permeability brought about
by insulitis in individuals with recent-onset diabetes [65].
Intravenously infused SPIOs preferentially accumulated in
t h ep a n c r e a so fp a t i e n t sw i t hi n s u l i t i sa sar e s u l to fi n c r e a s e d
vascular leakage and macrophage uptake. The study also
revealed differences in pancreatic volume between type 1
diabetic patients and healthy controls. These findings are in
line with the results of previous studies that used [
18F]-FDG
PET to detect insulitis in a mouse model of type 1 diabetes
[66] and in humans [67].
Transplanted islets
Isolated islets can be pre-labelled with large amounts of
contrast agents, prior to transplantation. However, labelling
can be difficult since islet cells have modest phagocytic
activity. Furthermore, the nature (e.g. metallic particles)
and large size of some MRI labels (e.g. liposomes
>300 nm in diameter) can further hinder uptake and affect
islet function and viability. Label uptake can be enhanced
using contrast agent with special coatings [68, 69], specific
antibodies [70], encapsulation of the agent in specially for-
mulated liposomes [71] or binding to positively-charged
peptides loaded by electroporation [72]. Several of these
approaches are not easily translatable to the clinic owing
to their experimental nature, or financial or logistical diffi-
culties. Direct labelling is possible using gadolinium or iron
oxide chelates [73, 74]. Recent findings, however, indicate
that heavy metal chelates can be toxic in humans, and this
may restrict their clinical use [75]. A further approach used
to greatly increase label uptake is to encapsulate the islets in
permeable capsules together with the MRI agent [76–79].
However, the actual status of the islets within the capsules
and their long-term fate is not known.
MRI contrast agents, most often iron oxide or gadolinium
chelates, function by affecting the local contrast of an im-
age. Typically, iron oxide results in regions of hypointensity
(dark spots), while gadolinium results in regions of hyper-
intensity (bright spots). In general, SPIOs show higher sen-
sitivity than other contrast agents. Accordingly, SPIO
particles have successfully been used for clinical cell track-
ing in melanoma patients [80]. Since MRI contrast agents
modify local contrast, they are greatly affected by the in
vivo background. This is a major hurdle in their clinical use,
especially in sites such as the liver, which are intrinsically
rich in iron and already hypointense (i.e. dark in typical
1252 Diabetologia (2012) 55:1247–1257MRI images). Indeed, in one study using SPIO-labelled
islets transplanted to the liver in humans some patients had
to be excluded due to their endogenously hypointense liver,
although it was possible to detect iron-induced dark spots up
to 6 months after islet transplantation in other patients [81].
Moreover, local image contrast can change in response to
various factors, including inflammation, bleeding or oedema,
further complicating positive localisation of transplanted
islets.
Another problem is the quantitative analysis of MRI
images obtained with contrast agents. Contrast agents are
not inherently quantitative, and spots on images may reflect
islet aggregates rather than single islets. This was docu-
mented by a study comparing in vivo MRI data with histol-
ogy and electron microscopy [82], which found that
absolute quantification of BCM was not possible with
SPIOs [83]. Even if islets could be successfully imaged in
the liver and kidney capsules for a period of 30 days, some
of the dark spots observed at later time points were due to
extracellular iron aggregates and islets that were labelled but
damaged [82]. A further and relevant issue in terms of
quantification is saturation, which can occur even at rela-
tively low concentrations of contrast agents [84]. In conclu-
sion, the interpretation of data on labelled islets transplanted
in the liver is complex, due to possible false-positives and
contrast saturation issues. Special imaging sequences can be
used to generate hyperintense regions after use of SPIOs
[84], which typically induce hypointense spots. The hyper-
intense appearance improves the visualisation and definition
of structures, even though contrast change remains subject
to the saturation effect mentioned earlier. Therefore the
technique is most applicable to low numbers of islets.
Analternativetocontrastagentsis
19FMRI.Thistech ni que
is not influenced by tissue background and allows absolute
quantification from in vivo images without signal satu-
ration at higher concentrations [85, 86]. For example,
diabetogenic,
19F-labelledTcellshavebeentrackedandquan-
tified as they homed to the pancreas [87]. The approach is still
in the early stages of development and has not yet been
applied to clinical imaging, although clinically applicable
agents are being tested [88]. The
19F signal is easily identified
and quantified, but the concentration of label required for
detection is about as high as that for paramagnetic contrast
agents, such as gadolinium chelates, and is several orders of
magnitude higher than for supermagnetic agents, such as iron
oxides [88]. Total imaging time is also longer with
19FM R I .
It is important to consider that labels may be taken up by
different islet cells, e.g. only beta cells vs several endocrine
and non-endocrine cell types, or even retained within the
islet capsule. As MRI resolution is seldom sufficient to
visualise single islets, the pattern of intra-islet labelling
may not significantly affect the data interpretation, provided
that it quantitatively reflects BCM and/or beta cell function.
Evaluation of these variables requires parallel microscopy
on either excised tissue sections or isolated islets labelled
prior to transplantation, as well as secretion studies on the
latter islets. Whenever the label may not be directly visible
by microscopy, a bimodal agent such as a fluorescent nano-
particle [89] is advantageous.
Damage to liver tissue after islet transplantation is detect-
able by imaging and may provide indirect information about
the viability of the islets. For example, intraportal islet
transplantation triggers hepatic steatosis, probably caused
by the locally high insulin secretion [90, 91]. Although the
link between steatosis and graft function remains unclear, it
appears that patients who develop fatty livers require more
intense exogenous insulin therapy. Liver steatosis can also
be observed using ultrasound, which is a much cheaper
alternative to MRI. Furthermore, damage to the hepatic
portal vein after islet transplant can also result in de-
tectable liver ischaemia [58] and embolism of the portal
vein in humans after islet transplantation [92]. Lastly,
the recent introduction of responsive MR agents (chem-
ical exchange saturation transfer [CEST] or paramagnetic
chemical exchange saturation transfer [PARACEST]) also
holds great promise for islet imaging. These agents can be
usedtodetecttissuevariationsinpH,redoxstate,oxygenation
or metabolite levels [93–95].
Future directions
The data and considerations summarised above show that
much remarkable progress has been made towards the in
vivo imaging of native and transplanted islets during the last
15 years of research on this topic. Several approaches are
already available for basic research studies of animal mod-
els, which allow direct visualisation of individual islets,
including those that do not require any pre-labelling [96],
or provide sound quantitative estimates of BCM in an
almost fully non-invasive way [97]. These methods can help
to advance our understanding of unresolved questions on the
naturalhistoryoftype1andtype2diabetes.Yet,noneofthese
approachesissimpleandcombinesallthemethodologicaland
practical features that are required for a ready-to-go approach
to BCI. Furthermore, even if the existing methods have pro-
vided the necessary proof of principle of concepts and meth-
odological steps, their translation to the clinic is hindered by
several ethical, safety and technological factors and is com-
plicatedbythe specifichistologicaland anatomicalfeaturesof
the human pancreas. To outline where the field should be
going, we thought to review here the major obstacles as well
as conceivable future directions for this undertaking.
There is an urgent need to develop a beta cell-specific
tracer that features an acceptable bioavailability to pancre-
atic islets once injected into the circulation. As stressed
Diabetologia (2012) 55:1247–1257 1253above, such an ideal tracer is not yet available, and many
independent efforts are under way to develop and validate
potential tracers. Ideally, such a tracer should target a mol-
ecule that is abundant at the surface of beta cells or, alter-
natively, be incorporated by them. To be useful in clinical
imaging, the target molecule should not be affected by the
chronic inflammatory environment that is typical in type 1
diabetes. The search for candidates has, so far, been based
on the screening of genomic, single nucleotide polymor-
phism and proteomic beta cell databanks, and this has not
yet identified an ideal candidate [98]. An exciting avenue of
research is the screening of all transcribed mRNAs (includ-
ing splice variants of each gene) to generate splice junction
databases, an approach that has already identified some beta
cell-specific variants [99]. Of note, inflammatory mediators
may also modify the splicing of beta cell genes [100], which
opens interesting possibilities for the imaging of inflamed
beta cells. Another alternative is the simultaneous targeting
of multiple molecules on the beta cell surface using many
specific ligands, on the assumption that the stoichiometry
and distribution of the targets on beta cells are not shared by
other cell types. A further interesting development is the
multimerisation of the selected probes, which is expected to
enhance the affinity of the ligand–target interaction, as well
as the internalisation of the target–ligand complex [101]. In
this approach, multiple copies of different ligands would be
taken via the circulation to the beta cells by a biodegradable
scaffold that could be labelled for detection by multiple im-
aging modalities [102]. A combination of the three latter
innovations could allow the construction of the, so far, elusive
beta cell-specific probe.
Another challenging step is the production of suitable
ligands. Ideally, one would like to retain the exquisite affin-
ity and specificity of antibodies, although these tend to have
limited pancreatic islet access because of their large size and
limited vascular extravasation. From this perspective, inter-
esting experiments are under way to produce smaller Ig or
Ig-like molecules, such as single chain antibodies, Affibod-
ies or camelid nanobodies [103]. Given that safety and cost
issues may hinder the use of antibodies or Ig-like molecules
in clinical studies, a painstaking, but promising alternative is
the search for other types of small molecule that exhibit
better tolerance and accessibility and cost less. With the
notable exception of DTBZ [5], whose beta cell specificity
is already much discussed [7], the results of such a search
has so far been limited. The use of high-throughput methods
to screen for large numbers of compounds in cultures of
insulin-producing or unrelated cells is expected to change
this situation. The search for such ligands, whatever their
chemical nature, should be fuelled by the large number of
physiological and cell biological studies that investigate
insulin secretion, as well as those concerning beta cell
survival, proliferation and apoptosis. Indeed, the ultimate
aim will be to image BCM and beta cell function, possibly
in a single imaging session. Thus, candidates should be
tested for their short- and long-term effects on different
aspects of beta cell function. To date, only manganese has
entered the first steps of such a screening [57, 104, 105].
However, the respective effects of BCM and beta cell func-
tion on the manganese-induced MRI signal remain to be
established. The comparison of animal models featuring
obvious differences in beta cell function in the presence of a
similar BCM will be instrumental to unambiguously address
this question.
With regard to imaging approaches, it is evident that the
different characteristics of clinically adaptable techniques
imposetheircombinationinamultimodalityimagingstrategy.
Only such a combined approach is likely to overcome the
shortcomings of the individual methods, in order to provide
coherent and quantitative information on both BCM and
function. This will require the adaptation of the existing
equipment, raising substantial technological and image anal-
ysis challenges. The recent introduction of responsive MR
agents (CEST, or PARACEST) holds great promise [93–95].
As in all innovative scientific endeavours, it is not pos-
s i b l et om a k es a f ep r e d i c t i o n so ft h eo u t c o m eo ft h e s e
developments and the time-line they will require to be
implemented. The close collaboration between islet biolo-
gists, diabetologists, radiologists, nuclear medicine physi-
cians, radiochemists and physicists, which is essential for
progress towards in vivo BCI, will undoubtedly generate
much novel information about beta cell biology and diabe-
tes. It is therefore most appropriate that such an integrative
effort is now being facilitated worldwide, particularly in
Europe, by several devoted programmes and sponsored by
the main scientific, national and international foundations.
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